Aspira Women’s Health Inc. (NASDAQ:AWH – Get Free Report) was the target of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 379,300 shares, an increase of 45.0% from the August 31st total of 261,600 shares. Based on an average trading volume of 123,400 shares, the days-to-cover ratio is presently 3.1 days. Currently, 3.4% of the company’s shares are sold short.
Aspira Women’s Health Price Performance
Shares of AWH stock remained flat at $0.83 during trading hours on Friday. The stock had a trading volume of 60,038 shares, compared to its average volume of 69,693. The company has a market capitalization of $10.27 million, a PE ratio of -0.57 and a beta of 1.48. Aspira Women’s Health has a 12-month low of $0.74 and a 12-month high of $6.01. The business’s 50 day moving average is $1.06 and its two-hundred day moving average is $2.01.
Aspira Women’s Health (NASDAQ:AWH – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. The firm had revenue of $2.42 million for the quarter, compared to the consensus estimate of $2.60 million. During the same quarter in the prior year, the firm earned ($0.28) earnings per share. Analysts expect that Aspira Women’s Health will post -1.26 earnings per share for the current year.
Analysts Set New Price Targets
View Our Latest Analysis on AWH
Institutional Investors Weigh In On Aspira Women’s Health
A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. lifted its position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH – Free Report) by 43.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 179,371 shares of the company’s stock after purchasing an additional 53,997 shares during the quarter. B. Riley Wealth Advisors Inc. owned about 1.73% of Aspira Women’s Health worth $732,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 12.19% of the company’s stock.
About Aspira Women’s Health
Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.
Read More
- Five stocks we like better than Aspira Women’s Health
- With Risk Tolerance, One Size Does Not Fit All
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- What are earnings reports?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Investing In Preferred Stock vs. Common Stock
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Aspira Women's Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspira Women's Health and related companies with MarketBeat.com's FREE daily email newsletter.